| (Values in U.S. Thousands) | Mar, 2022 | Mar, 2021 | Mar, 2020 | Mar, 2019 | Mar, 2018 |
| Sales | 6,730,410 | 6,071,860 | 6,399,710 | 5,785,510 | 5,400,490 |
| Sales Growth | +10.85% | -5.12% | +10.62% | +7.13% | +7.72% |
| Net Income | 426,790 | 395,920 | 1,120,260 | 570,470 | 466,610 |
| Net Income Growth | +7.80% | -64.66% | +96.37% | +22.26% | +27.48% |
Eisai Ltd ADR (ESALY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America.
Fiscal Year End Date: 03/31